-
Getting Into The Drug Business: From NDAs To PDUFA Dates
Tuesday, September 27, 2016 - 2:20pm | 665Read More...The strongest catalysts for a pharma stock are the various milestones on the road to FDA approval for new drugs. For new investors, they’ll often see a stock rise astronomically, but, when they go to make sense of the reasons for the jump, they’re greeted with unfamiliar acronyms. Let...
-
What Maxim Thinks Of Cytori After Its Huge Week
Wednesday, April 8, 2015 - 12:53pm | 188Read More...In a report published Wednesday, Maxim Group analyst Jason Kolbert discussed Cytori Therapeutics Inc (NASDAQ: CYTX)'s announcement earlier this week that the European Medicines Agency Committee for Orphan Medicinal Products has designed Cytori's ECC S-50 cellular therapeutic as an orphan...
